Post-marketing Active Surveillance of Guillain Barré Syndrome Following COVID-19 Vaccination in Persons Aged ≥12 Years in Italy: A Multi-database Self-controlled Case Series Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jan 19

PMID 38241309

Authors

Cristina Morciano

Stefania Spila Alegiani

Francesca Menniti Ippolito

Valeria Belleudi

Gianluca Trifiro

Giovanna Zanoni

Aurora Puccini

Ester Sapigni

Nadia Mores

Olivia Leoni

Giuseppe Monaco

Elena Clagnan

Cristina Zappetti

Emanuela Bovo

Maria Cutillo

Roberto Da Cas

Marco Massari

Affiliations

Soon will be listed here.

Abstract

Background: Recently published studies have reported association of COVID-19 vaccine ChAdOx1-S (Vaxzevria) with Guillain Barré Syndrome (GBS). Less is known about the safety of other COVID-19 vaccines with respect to GBS outcome. This study investigated the association of COVID-19 vaccines with GBS in more than 15 million persons aged ≥12 years in Italy.

Methods: Study population was all individuals aged ≥12 years who received at least one dose of COVID-19 vaccines, admitted to emergency care/hospital for GBS from 27 December 2020-30 September 2021 in Italy. Identification of GBS cases and receipt of at least one dose of mRNA-1273 (Elasomeran), BNT162b2 (Tozinameran), ChAdOx1-S (Vaxzevria) and Ad26.COV2.S (Janssen) through record linkage between regional health care and vaccination registries. Relative Incidence (RI) was estimated Self-controlled case series method adapted to event-dependent exposure using in the 42-day exposure risk period after each dose compared with other observation periods.

Results: Increased risk of GBS was found after first (RI = 6.83; 95% CI 2.14-21.85) and second dose (RI = 7.41; 2.35-23.38) of mRNA-1273 and first dose of ChAdOx1-S (RI = 6.52; 2.88-14.77). Analysis by age found an increased risk among those aged≥60 years after first (RI = 8.03; 2.08-31.03) and second dose (RI = 7.71; 2.38-24.97) of mRNA-1273. The first dose of ChAdOx1-S was associated with GBS in those aged 40-59 (RI = 4.50; 1.37-14.79) and in those aged ≥ 60 years (RI = 6.84; 2.56-18.28).

Conclusions: mRNA-1273 and ChAdOx1-S vaccines were associated with an increased risk of GBS however this risk resulted in a small number of excess cases. Limitations were loss of GBS outpatient cases and imprecision of the estimates in the subgroup analysis due to a low number of events.

Citing Articles

Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.

Meo S, Shaikh N, Abukhalaf F, Meo A Sci Rep. 2024; 14(1):18767.

PMID: 39138276 PMC: 11322667. DOI: 10.1038/s41598-024-66999-7.

Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study.

Morciano C, Massari M, Cutillo M, Belleudi V, Trifiro G, Mores N Drug Saf. 2024; 47(11):1157-1169.

PMID: 39068268 PMC: 11485117. DOI: 10.1007/s40264-024-01462-0.

Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021.

Mateo-Urdiales A, Fabiani M, Mayer F, Sacco C, Belleudi V, Da Cas R BMC Public Health. 2024; 24(1):1569.

PMID: 38862939 PMC: 11165887. DOI: 10.1186/s12889-024-19071-y.

References

Allen C, Ramsamy S, Tarr A, Tighe P, Irving W, Tanasescu R . Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol. 2021; 90(2):315-318. DOI: 10.1002/ana.26144. View

Trifiro G, Isgro V, Ingrasciotta Y, Ientile V, LAbbate L, Foti S . Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. BioDrugs. 2021; 35(6):749-764. PMC: 8507511. DOI: 10.1007/s40259-021-00498-3. View

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi S, Razvi S . Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12):2144-2153. PMC: 8629105. DOI: 10.1038/s41591-021-01556-7. View

Ogata S, Ishii Y, Asano K, Kobayashi E, Kubota S, Takahashi K . Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination. Intern Med. 2022; 61(11):1757-1760. PMC: 9259306. DOI: 10.2169/internalmedicine.8967-21. View

Trifiro G, Massari M, Da Cas R, Ippolito F, Sultana J, Crisafulli S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Saf. 2020; 43(12):1297-1308. PMC: 7450482. DOI: 10.1007/s40264-020-00994-5. View

Belleudi V, Rosa A, Finocchietti M, Poggi F, Marino M, Massari M . An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project. Front Pharmacol. 2022; 13:959267. PMC: 9521186. DOI: 10.3389/fphar.2022.959267. View

Spila Alegiani S, Crisafulli S, Rossi P, Mancuso P, Salvarani C, Atzeni F . Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021; 60(SI):SI25-SI36. PMC: 8083276. DOI: 10.1093/rheumatology/keab348. View

Walker J, Schultze A, Tazare J, Tamborska A, Singh B, Donegan K . Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine. 2022; 40(32):4479-4487. PMC: 9170533. DOI: 10.1016/j.vaccine.2022.06.010. View

Massari M, Spila Alegiani S, Morciano C, Spuri M, Marchione P, Felicetti P . Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. PLoS Med. 2022; 19(7):e1004056. PMC: 9333264. DOI: 10.1371/journal.pmed.1004056. View

10.

Weldeselassie Y, Whitaker H, Farrington C . Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011; 139(12):1805-17. DOI: 10.1017/S0950268811001531. View

11.

Patel S, Khurram R, Lakhani A, Quirk B . Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021; 14(4). PMC: 8070856. DOI: 10.1136/bcr-2021-242956. View

12.

Hanson K, Goddard K, Lewis N, Fireman B, Myers T, Bakshi N . Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022; 5(4):e228879. PMC: 9044108. DOI: 10.1001/jamanetworkopen.2022.8879. View

13.

Whitaker H, Farrington C, Spiessens B, Musonda P . Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2005; 25(10):1768-97. DOI: 10.1002/sim.2302. View

14.

Benedetti M, Pugliatti M, DAlessandro R, Beghi E, Chio A, Logroscino G . A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. Neuroepidemiology. 2015; 45(2):90-9. DOI: 10.1159/000438752. View

15.

Petersen I, Douglas I, Whitaker H . Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016; 354:i4515. DOI: 10.1136/bmj.i4515. View

16.

Ghebremichael-Weldeselassie Y, Jabagi M, Botton J, Bertrand M, Baricault B, Drouin J . A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety. Stat Med. 2022; 41(10):1735-1750. PMC: 9303905. DOI: 10.1002/sim.9325. View

17.

Wilson K, Hawken S . Drug safety studies and measures of effect using the self-controlled case series design. Pharmacoepidemiol Drug Saf. 2012; 22(1):108-10. DOI: 10.1002/pds.3337. View

18.

Farrington C, Whitaker H, Hocine M . Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2008; 10(1):3-16. DOI: 10.1093/biostatistics/kxn013. View

19.

Massari M, Spila-Alegiani S, Fabiani M, Belleudi V, Trifiro G, Kirchmayer U . Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study. Vaccines (Basel). 2021; 9(7). PMC: 8310185. DOI: 10.3390/vaccines9070716. View

20.

Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa P . Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021; 13(2):e13426. PMC: 7978140. DOI: 10.7759/cureus.13426. View